In eukaryotic cells, when exposed to certain types of stress including hypoxia, eIF2a is phosphorylated by several kinases including protein kinase R (PKR) and PKRlike endoplasmic reticulum kinase (PERK). Subsequently, protein translation is stopped and stress granules (SGs) are formed. Cancer cells form SGs under hypoxia. SGs accumulate apoptosis-related molecules and play anti-apoptotic roles. Thus, hypoxiainduced SG formation contributes to drug resistance in cancer cells. For this reason, inhibition of SG formation is expected to be beneficial in cancer therapy. To prove this concept, chemical reagents that inhibit SG formation are required as experimental tools. We searched for chemical compounds that suppress SG formation and identified that b-estradiol, progesterone, and stanolone (hereafter described as EPS) inhibit SG formation in human cervical cancer HeLa cells. As it turned out, EPS block PKR but not PERK, thus fail to suppress SG formation in most cancer cells, where SGs are formed via PERK. Nevertheless, in this study, we used HeLa cells as a model and demonstrated that EPS block hypoxia-induced SG formation in HeLa cells and consequently reduce drug resistance that HeLa cells acquire under hypoxia. Our findings support that inhibition of SG formation is a useful method to control cancers.
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Eukaryotic cells, when exposed to certain types of stress, stop protein translation and form cytoplasmic, nonmembranous, phase-dense structures called stress granules (SGs) (13) . SGs are composed of translation initiation factors, 40S ribosomal subunits, diverse RNA-binding proteins, and translationally stalled mRNAs (4) . After cells are relieved from stress, SGs are dispersed and protein translation is recovered. In this manner, under stressful conditions, eukaryotic cells divert limited resources from synthesis of dispensable proteins to survive stress. It is reasoned that the impairment of SG formation should compromise cell viability and underlie various pathological conditions. Indeed, neurons under endoplasmic reticulum (ER) stress adopt a cell death fate when SG formation is suppressed (5) . Moreover, neurons that are preconditioned by proteasome inhibition or burdened with mutant tau protein fail to form SGs in response to acute hyperthermia, which leads to possible loss of SGs and compromise protective roles of SGs in neurodegenerative diseases (6) . These findings imply that the disorder of SG formation is implicated in the pathophysiology of neurodegeneration caused by abnormal proteins. Conversely, cancer cells utilize SG formation to acquire drug resistance and to escape from anti-cancer drug therapy (7, 8) . In this regard, inhibition of SG formation is expected to make cancer cells vulnerable to anti-cancer drugs. Accordingly, it is shown that the inhibition of eIF2a phosphorylation by enforced expression of dominant negative eIF2a sensitizes glioma cells to anti-cancer drugs (9) . However, considering the clinical application, we need to verify that inhibition of SG formation by drug interventions enhances the sensitivity of cancer cells against anti-cancer therapies. For this purpose, we have to obtain such compounds that block SG formation. Cycloheximide, an inhibitor of protein synthesis, is well known to suppress SG formation (10) . However, cycloheximide itself is cytotoxic and thus unsuitable for this purpose. With this in mind, we performed a screening for compounds that suppress SG formation in human cervical cancer HeLa cells. As a consequence, we found that b-estradiol, progesterone and stanolone (hereafter described as EPS for short) block SG formation in HeLa cells. HeLa cells form SG under hypoxia and become resistant against cancer drugs such as cisplatin and paclitaxel. However, EPS-treated HeLa cells fail to form SG under hypoxia and become sensitive against cisplatin and paclitaxel. Notably, EPS neither compromise cell viability nor enhance drug sensitivity of HeLa cells under normoxia. Moreover, overexpression of G3BP1, a key component of SG, recovers SG formation in EPStreated HeLa cells and re-confers drug resistance to the cells. These findings support the assumption that SG formation is instrumental for cancer cells to acquire drug resistance under hypoxia. What is more important, the combination therapy of cytotoxic drugs and inhibitors of SG formation can be a reasonable choice for cancer therapy.
Materials and Methods
DNA constructions and virus productions pCIneoMyc and pCIneoEGFPC2 vectors were described previously (11) . Human cDNA of G3BP1 was obtained by PCR using primers (H3604, 5 0 -acgcgtgaattcatggtgatggagaagcctagtcc-3 0 and H3605, 5 0 -agtcgactcactgccgtggcgcaagcccccttcc-3 0 ) on the mixture of human lung and kidney cDNA libraries (Clontech Laboratories, Inc., Mountain View, CA, USA). PCR product was digested with EcoRI and Sall and ligated into the same sites of pCIneoMyc and pCIneoEGFPC2 to generate pCIneoMyc-G3BP1 and pCIneoGFP-G3BP1. pFlagx3-PERK and pCAG-Flag-PKR are generous gifts from Akihiro Tomita (Japanese Foundation for Cancer Research) and Koichi Watashi (National Institute of Infectious Diseases), respectively.
Antibodies and reagents
Antibodies and reagents were obtained from commercial sources: mouse monoclonal anti-G3BP1 (sc-81940) and mouse monoclonal anti-TIA1 (sc-166247) (Santa Cruz Biotechnology, Dallas, TX, USA); rabbit polyclonal anti-eIF2a (D7D3) XP (5324) and rabbit polyclonal anti-phospho-eIF2a (Ser51) (9721) (Cell Signaling Technology, Danvers, MA, USA); rabbit polyclonal eIF4G1/eIF4GI (A300-502A) (Bethyl Laboratories, Inc., Montgomery, TX, USA); rabbit polyclonal anti-phospho-PKR (Thr451) (07-886) (Merck, Kenilworth, NJ, USA); anti-DYKDDDDK-tag (014-22383), paclitaxel (169-18611) (Wako Pure Chemical Industries, Osaka, Japan): rabbit polyclonal anti-Myc (562) (Medical & Biological Laboratories Co. Ltd., Nagoya, Japan); fulvestrant (10011269), G-15 (14673), GSK2606414 (17376) and PKR inhibitor (15323) (Cayman Chemical Company, Ann Arbor, MI, USA); arsenite (71287), b-estradiol (E2758) and progesterone (P-0130) (Sigma-Aldrich, St. Louis, Dallas, TX, USA); cisplatin (D3371) and stanolone (A0462) (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan); thapsigargin (33637-31) (nacalai tesque, Tokyo, Japan); peroxidase-conjugated goat anti-mouse (0855550) and anti-rabbit (0855676) secondary antibodies (MP Biomedicals, Santa Ana, CA, USA); and Alexa Fluor 
RNA interference
RNA interferences were performed by use of Lipofectamine RNAiMAX (Thermo Fisher Scientific). General control nonderepressible 2 (GCN2) siRNA (sc-45644) and heme-regulated inhibitor (HRI) siRNA (sc-39052) were obtained from Santa Cruz Biotechnology.
Cell cultures under hypoxia
Hypoxia experiments were performed using BIONIX system (Sugiyama-gen Co., Tokyo, Japan) according to the manufacturer's protocol. In brief, cells were cultured in culture plates and placed in a plastic bag with a capsule of deoxidizing agent together with an oxygen meter. The bag was sealed with a clip apart from the deoxidizing agent immediately when O 2 concentration reached 0.5%. Then the bag was cultured in a CO 2 incubator for the indicated periods of time.
Chemical compound libraries A total of 4,018 validated chemical compounds were obtained from TMDU Chemical Biology Screening Center and Drug Discovery Initiative (the University of Tokyo).
Immunofluorescence staining
Immunofluorescence staining for detecting SGs was performed as described previously (5) .
Immunoblotting analyses
Appropriate amounts of proteins were resolved by SDSPAGE and transferred onto nitrocellulose membranes. After blocking with 4.0% (w/v) skim milk, membranes were probed with appropriate antibodies and visualized using enhanced chemiluminescence detection with either Amerscham TM ECL TM Western Blotting Detection Reagents (GE Healthcare UK Ltd.) or Chemi-Lumi One Ultra (nacalai tesque). Cell proliferation and viability assessment Cell proliferation and viability were assessed using MTT formazan dye conversion (12) .
Quantification of SG

FACS analysis
Cells were washed with PBS, fixed with 70% (v/v) ethanol in PBS overnight at À20 C, and stained with 10 mg/l propidium iodide in PBS containing 100 mg/l RNaseA for 15 min. For analysing green fluorescent protein (GFP)-positive cells, cells were gated and at least 5 Â 10 3 GFP-positive cells were analysed.
Statistical analysis
Statistical analyses were performed with Student's t-test for the comparison between two samples and analysis of variance (ANOVA) with Dunnett's test for the multiple comparisons using the GraphPad Prism 5.0 (GraphPad Software).
Results
Chemical library screening to identify compounds that inhibit SG formation in HeLa cells
With the aim of identifying compounds that suppress SG formation, we applied 10 mM of 4,018 small chemical compounds to HeLa cells or MCF-7 cells. Twenty-four hours later, arsenite was added to a final concentration of 250 mM. Thirty minutes later, the cells were fixed and were immunostained with anti-G3BP1 antibody. Almost 100% of the cells showed SG formation with arsenite treatment alone. Then we evaluated the percentage of the cells forming SGs and selected compounds that reduced SG formation down to 30% as candidates for SG inhibitors. Cycloheximide, a well-known inhibitor of SG formation, was selected with this criterion as a candidate that suppresses SG formation, supporting the validity of our screening. Besides cycloheximide, however, only three compounds, EPS, showed significant suppression of SG formation in HeLa cells ( Fig. 1A and B) . On the other hand, EPS did not suppress SG formation in MCF-7 cells (Fig. 1C) . In attempting to confirm the effect of EPS on SG formation in other cancer cells, we treated human colon HCT116, breast cancer MDA-MB-468, pancreatic cancer PANC-1, bladder cancer 5637, RT4 and ovarian cancer OVCAR-5 cells. Surprisingly, EPS failed to suppress arsenite-induced SG formation in all those tested cells except HeLa cells ( Supplementary Fig. S1 ). To compare the inhibitory effect of E, P and S, we used E, P and S at various doses. E, P and S were effective at 1 mM but not at 0.5 mM, suggesting IC50 is between 0.5 and 1 mM for all three compounds ( Supplementary Fig. S2 ). EPS-suppressed SG formation induced not only by arsenite but also by heat shock in HeLa cells (Fig. 1D ).
EPS suppress eIF2a phosphorylation in HeLa cells and may target protein kinase R (PKR)
The above findings imply that HeLa cells have some different property from other cancer cells regarding SG formation. SG is formed when protein translation initiation is impaired (2, 3). Protein translation initiation starts with the assembly of a 43S preinitiation complex composed of eIF1, eIF2, eIF3 and eIF5 with the 40S ribosomal subunit (13) . The 43S complex binds 7-methyl guanosine-capped mRNA and the associated initiation factors such as eIF4E, eIF4G and poly(A)-binding protein to form the 48S complex. In most cases, SG formation is triggered by the phosphorylation of eIF2a. Hence, we investigated whether EPS had an effect on eIF2a phosphorylation. EPS suppressed the phosphorylation level of eIF2a in HeLa cells ( Fig. 2A ), but not in MCF-7 cells (Fig. 2B ). When cells were exposed to arsenite. eIF2a is phosphorylated mainly by four stress-sensing serine/threonine kinases; PKR, PERK, GCN2 and HRI, which are activated by different types of stress (14) . While PKR senses heat and oxidative stress, PERK detects ER stress. GCN2 monitors amino acid starvation, and HRI senses oxidative stress and heme deficiency and is also activated by bortezomib, a 26S proteasome inhibitor (15) . We raised a question in which kinase contributes to eIF2a phosphorylation in HeLa cells. First, we treated HeLa cells with PERK inhibitor (GSK2606414) and PKR inhibitor, and found that the former had no effect on arsenite-induced SG formation, while the latter reduced SG-positive cells to 50% (Fig. 3A) . We next knocked down GCN2 and HRI. GCN2 silencing had no effect on arsenite-induced SG formation, but HRI silencing remarkably suppressed it (Fig. 3A) . These findings suggest that in HeLa cells, PKR and HRI may be responsible of eIF2a phosphorylation in response to arsenite treatment. Intriguingly, thapsigargin, which triggers SG formation through PERK activation in most cells, did not induce SG formation in HeLa cells (Fig. 3B) . Together with the above-described result that PERK is not involved in arsenite-induced SG formation, we speculated that PERK expression may be low in HeLa cells. Indeed, qRT-PCR analysis demonstrated that HeLa cells express relatively low level of PERK compared with in MCF-7 cells (Fig. 3C) . We speculated that EPS suppress PKR and HRI activities, but not PERK activity, and that in most cells other than HeLa cells, PERK phosphorylates eIF2a to trigger SG formation. If this is the case, it is comprehensible that EPS suppression of SG formation is only observed in HeLa cells. To verify this speculation, we attempted to evaluate the phosphorylation level at threonine 451 of endogenous PKR, which is essential for PKR activation (16) . However, the phospho-PKR antibody failed Pharmacological approach to the roles of stress granules to detect phosphorylation of endogenous PKR (data not shown). Alternatively, we expressed Flag-PKR exogenously and examined the effect of EPS on PKR activation. Overexpression of PKR itself induced PKR phosphorylation (Fig. 4A , the first and second lanes) and this phosphorylation was suppressed by EPS treatment (Fig. 4A , the third to fifth lanes). SG formation induced by Flag-PKR expression (Fig. 4B , an arrow) was also suppressed when cells were treated with EPS (Fig. 4B) . Furthermore, when PERK was exogenously expressed in HeLa cells, thapsigargin strongly induced SG formation, and EPS did not suppress thapsigargin-PERK-induced SG formation (Fig. 4C, arrows) . Threonine 485 phosphorylation is reported to be essential for HRI activity (17) . As no antibody that detects threonine 485 of HRI is available, we cannot directly examine the effect of EPS on HRI autophosphorylation. However, we conjecture that EPS suppress not only PKR but also HRI. This assumption remains to be verified.
b-Estradiol may suppress SG formation via G-protein coupled oestrogen receptor 1 (GPER) We next raised an obvious question whether EPS suppress SG formation through steroid hormone receptors. EPS bind to distinct receptors (18, 19) . Hence, for the simplicity, we focused on b-estradiol. As there are numerous oestrogen receptors, we avoided a knockdown approach and used fulvestrant, a downregulator of oestrogen receptors (20) . Unexpectedly, b-estradiol suppressed arsenite-induced SG formation even in the presence of fulvestrant (Fig. 5A) . b-Estradiol also binds to GPER (21) . Thus, we next treated HeLa cells with G-15, a selective GPER antagonist, and observed that G-15 attenuated the b-estradiol-mediated suppression of SG formation (Fig. 5B) . These results suggest that the inhibitory effect on SG formation of b-estradiol is a non-genomic action mediated by GPER. Progesterone and stanolone also bind to membrane receptors (22) . Although we do not directly address this question, we speculate that progesterone and stanolone also suppress SG formation through membrane G protein-coupled receptors.
HeLa cells form SG and acquire drug resistance under hypoxia The above findings mean that EPS can be used as tools to suppress SG formation only in HeLa cells. Although this observation is disheartening, our initial aim of this study is to prove the concept that inhibition of SG formation enhances drug sensitivity and is a beneficial for cancer therapy. We therefore decided to use the combination of EPS and HeLa cells as a model to test the concept. As a prerequisite for further studies, we first tried to find out the condition under which SG formation is implicated in the drug resistance in HeLa cells. In rapidly growing tumours, cancer cells are exposed to hypoxia. Hypoxia triggers adaptive metabolic responses in cancer cells and causes drug resistance (23, 24) . Hypoxia also increases production of reactive oxygen species and induces SG formation, which may be mediated by PKR (25) . Considering the predominant role of PKR in HeLa cells, we cultured HeLa cells under hypoxia for 24 h. As expected, hypoxia induced eIF2a phosphorylation and SG formation (Fig. 6A , the left and the right, hypoxia-). EPS suppressed hypoxia-induced SG formation (Fig. 6A , the right, hypoxia, b-estradiol, progesterone and stanolone). We exposed HeLa cells to various doses of cisplatin and paclitaxel, which are widely used as anti-cancer drugs, for 48 h and confirmed that HeLa Pharmacological approach to the roles of stress granules cells became resistant against these drugs under hypoxia (Fig. 6B) .
EPS enhance drug sensitivity of HeLa cells under hypoxia
In MTT assay, EPS did not compromise the cell viability in HeLa cells without drug treatment under hypoxia (Fig. 6C) . We also confirmed that the short exposure to hypoxia did not change cell cycle distribution and that EPS did not alter it either (Fig. 6D) . Nevertheless, EPS suppress hypoxia-induced SG formation (Fig. 6A) . Thereby, if EPS affect the hypoxia-induced drug resistance of HeLa cells, we could attribute, if not completely, the effect of EPS to the inhibition of SG formation. EPS did not alter cisplatin sensitivity in HeLa cells under normoxia (Fig. 7A) . EPS slightly enhanced paclitaxel sensitivity under normoxia (Fig. 7B) . EPS enhanced cisplatin sensitivity under hypoxia, and thus HeLa cells came to respond to cisplatin as well as under normoxia (Fig. 7A and C) . EPS also recovered paclitaxel sensitivity under hypoxia, but the recovery was only partial (Fig. 7D) . As shown in Fig. 6B , CDDP, when used at higher doses, overcomes drug resistance and suppresses the viability of HeLa cells under hypoxia. In contrast, paclitaxel, even when used at higher doses, cannot suppress the viability of HeLa cells under hypoxia. It means that HeLa cell acquire more durable drug resistance against paclitaxel than against CDDP. This may be the reason why EPS cannot fully abolish paclitaxel resistance of HeLa cells under hypoxia (Fig. 7D) . Importantly, EPS did not reduce the expression of hypoxia-inducible factor-1 (HIF) a target genes, SCL2A1 (human GLUT1 gene) and VEGFA (human vascular endothelial growth factor gene) (Fig. 7E) . That is, EPS do not antagonize all effects of hypoxia in HeLa cells. Pharmacological approach to the roles of stress granules G3BP1 overexpression recovers SG formation and drug resistance in EPS-treated HeLa cells under hypoxia To corroborate that the effect of EPS is indeed related to the inhibition of SG formation, we tried to recover SG formation in EPS-treated HeLa cells and tested whether and how the drug resistance was regained. To this end, we exogenously expressed G3BP1 in HeLa cells and cultured them either under normoxia or hypoxia. As shown in Fig. 7A , treatment with 5.0 mg/ml cisplatin for 48 h reduced the cell viability to 10% under normoxia. Under hypoxia, cell viability was recovered up to 60%, while it was decreased to 20% when cells were treated with EPS. Therefore, we adopted this condition for the following experiments and confirmed the effect of hypoxia and EPS on CDDP-induced nuclear condensation in the immunofluorescence (Fig. 8A) . Under normoxia, almost all cells showed nuclear condensation after 48 h exposure to 5.0 mg/ml cisplatin (Fig. 8A, normoxia) . In contrast, under hypoxia, cells became resistant to cisplatin and did not show nuclear condensation (Fig. 8A, hypoxia, -) . On the other hand, when cells were treated with EPS, nuclear condensation was observed (Fig. 8A, hypoxia , b-estradiol, progesterone and stanolone, arrowheads). We evaluated sub-G1 population after the treatment with 5 mg/ml CDDP for 48 h in FACS analysis. Hypoxia remarkably reduced sub-G1 population (from 21% to 10.4%), but EPS recovered it (Supplementary Fig. S3A ). These findings support that EPS make HeLa cells vulnerable to cisplatin under hypoxia. We performed the same experiments using HeLa cells overexpressing G3BP1. As previously reported, HeLa cells expressing Myc-G3BP1 or GFP-G3BP1 formed SGs, which were also detected with anti-TIA1 antibody (Fig. 8B) (26) . G3BP1 induces small and large SGs in the dose-dependent manner and the formation of small SGs does not depend on eIF2a phosphorylation (27) . We confirmed that Myc-G3BP1 induced SG formation without eIF2a phosphorylation (Fig. 8B, the right) . Accordingly, Myc-G3BP1-induced SGs were not suppressed with EPS treatment (Fig. 8C) . We next exposed these cells to hypoxia with or without EPS, and treated them with 5.0 mg/ml cisplatin for 48 h. Most cells were viable and did not exhibit nuclear condensation without EPS treatment (Fig. 8D) . GFP-G3BP1 formed SGs, which were not suppressed by EPS (Fig. 8D, the bottom  panel, arrows) . Under the treatment with EPS, the cells without expressing GFP-G3BP1 showed nuclear condensation (Fig. 8D, the bottom panel, arrowheads) . However, the cells expressing GFP-G3BP1 did not show nuclear condensation (Fig. 8D) . In contrast, some part of control GFP-expressing cells showed nuclear condensation in the presence of EPS (Fig. 8D , the top panel, arrowheads). We sorted control GFP-and GFP-G3BP1-expressing cells by FACS and evaluated sub-G1 population. EPS increased sub-G1 population in control GFP-expressing cells, but not in GFP-G3BP1-expressing cells (Fig. 8D , the numbers under the images). These findings support that SG formation is associated with cisplatin resistance.
Discussion
Eukaryotic cells, when exposed to stress, form SGs composed of components of the translation machinery, RNA-binding proteins and mRNAs (2, 3) . SGs are proposed to protect mRNAs and provide the platform for deciding the fates of untranslated mRNAs among storage, degradation and re-initiation of translation. Thus, eukaryotic cells presumably use SG formation as a survival strategy under stress. However, it is not a straightforward task to experimentally verify this assumption. Autophagy depends on specific molecules such as ATG5 that work almost specifically for autophagy (28). We can get insights into the physiological significance of autophagy through the perturbation of such molecules. In contrast, crucial components of SG such as TIA1 and G3BP1 have other functions besides SG formation. TIA1 depletion blocks SG formation, but also interferes with RNA splicing (29) . The consequence of TIA1 silencing may be due to the dysregulation of RNA silencing. Likewise, as G3BP1 binds Ras GTPase-activating protein, some effect of G3BP1 silencing may be related to Ras signalling (30) . Therefore, we cannot discuss the significance of SG formation based on the consequence of depletion of SG components.
Rapidly growing cancer cells are exposed to hypoxic conditions, which enhances HIFs and triggers pleiotropic actions (23, 24, 31) . One of the consequences is SG formation (25) . In this study, we aimed to elucidate whether hypoxia-induced SG formation contributes to the drug resistance in cancer cells. The preceding study revealed that the inhibition of eIF2a phosphorylation reduces the drug resistance in gliomas, which suggests that inhibition of SG formation is useful in controlling cancers (9) . Nevertheless, as eIF2a is instrumental for translation, we cannot attribute the effect of the inhibition of eIF2a phosphorylation only to SG suppression. To address the significance of hypoxia-induced SG formation, we tried to identify reagents that inhibit SG formation in HeLa and MCF-7 cells. Among 4,018 validated chemical compounds, we obtained EPS (Fig. 1) . Unexpectedly, EPS suppress SG formation only in HeLa cells among eight cell lines tested in this study. This surprising observation prompted us to study the mechanism of SG formation in HeLa cells. We first revealed that among four kinases, which are known to phosphorylate eIF2a, PKR and HRI are involved in SG formation in HeLa cells, while neither PERK nor GCN2 is (Fig. 3) . EPS suppress PKR-mediated SG formation but not PERK-mediated SG formation (Fig. 4C) . We did not directly test the effect of EPS on HRI. However, as the inhibitory effect of EPS is more remarkable than that of PKR inhibitor or that of HRI silencing, we speculate that EPS suppress both PKR and HRI. We also found that G-15, but not fulvestrant, antagonizes the effect of b-estradiol. Thus, we speculate that EPS inhibit PKR and HRI through the non-genomic actions in HeLa cells and eventually block SG formation but that EPS cannot suppress SG formation in other cells, in which PERK plays a predominant role in SG formation. As we cannot find any significant difference among the effects of E, P and S, we consider that EPS, even though they bind to distinct membrane G-proteincoupled receptors, may use the same mechanism to suppress PKR and HRI.
The fact that EPS fail to block SG formation in most cancer cells is disappointing. Nevertheless, we used EPS as tools to perturb the hypoxia-induced SG formation in HeLa cells. EPS render HeLa cells more vulnerable against cisplatin and paclitaxel under hypoxia. EPS neither affect drug sensitivity in HeLa cells under normoxia, which do not form SGs, nor suppress the enhancement of HIF target genes that are irrelevant to SG formation. Furthermore, the induction of SG formation by G3BP1 overexpression, which cannot be suppressed by EPS, abolishes the effect of EPS. Hence, although we cannot completely exclude the possibility that EPS sensitize HeLa cells against drugs independently of the inhibition of SG formation, we conjecture that the recovery of the drug sensitivity Pharmacological approach to the roles of stress granules by EPS under hypoxia depends on the inhibition of SG formation.
In conclusion, this study supports the concept that the inhibition of hypoxia-induced SG formation is a rational method to enhance the effect of anti-cancer drug therapies. Needless to say, our current study has a limitation. To definitely prove this concept, we further need to find out other reagents that suppress SG formation in various cancer cells without directly compromising the cell viability.
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